AUTOIMMUNE TECHNOLOGIES

PSF Verified
830 Union Street, Suite 200, New Orleans, LA 70112, United States
Autoimmune Technologies, LLC specifies their major areas of research as: Anti-Viral Drugs, Rheumatic Diseases, and Other Diseases. Anti-Viral Drugs include: Influenza Drugs and MERS/SARS Drugs. Rheumatic Diseases Research include: Fibromyalgia Syndrome, Systemic Lupus Erythematosus, Sjogren's Syndrome, Juvenile Rheumatoid Arthritis, and Gulf War Syndrome. Other Diseases Research include: Lassa Fever, Ebola Fever, Graves' Disease, Non-HIV AIDS, and Breast Cancer.
DUNS #:
946839156
CAGE Code:
4CV15
Type:
Services Provider
Employees:
1-10
Annual Revenue:
Less than $1M
Year Founded:
1995
Country of Origin:
United States
Sectors Served:
US Federal
Company Security Level:
Unknown
Credit Card Usage:
Yes

Specialties and Expertise:

Anti-Viral Drugs, Therapeutic and Prophylactic Antibodies, Stem Cell Antibody Delivery, Anti-Viral Drugs, Rheumatic Diseases, Diagnostic and Therapeutic Technologies, Unique Human Monoclonal Antibo...

Contact/Location Info5

Size and minority status

Size
Small business
Ownership
African American
Alaska Native
Asian-Indian
Asian-Pacific
Hispanic
Minority-Unspecified
Native American
Native Hawaiian
Tribal
Unspecified
Veteran
Woman
Government Set-Aside Programs
AbilityOne
HUBZone
SBA 8(a)
SDVOSB
Small Disadvantaged Business (SDB)
Woman Owned Small Business (WOSB)

Commodity Codes7

PRODUCTS AND SERVICES2

Laboratory Tests
Autoimmune Technologies provides laboratory tests for diseases such as Fibromyalgia, Lassa Fever, Ebola Fever, Gulf War Syndrome, Lupus, Sjogren's, Juvenile RA, Graves' Disease, Breast Cancer, and Non-HIV AIDS.
FF-3 Drug
Autoimmune Technologies is developing FF-3, the First Cell-Entry-Inhibiting Influenza Drug, as a nasal and oral spray for treatment and post-exposure prevention of seasonal and pandemic flu.

Past experience4

SBIR
Peptide Drugs against Influenza Virus
Influenza virus is one of the most important human pathogens accounting for widespread morbidity and mortality. Influenza virus is c...
SBIR
Peptide inhibitors of coronavirus entry
The broad long-term objectives of the proposed work are to develop effective medical countermeasures to be used for the treatment of...
SBIR
Peptide inhbitors of influenza entry-FAST T...
Between 10% and 20% of the United State population suffer from seasonal influenza each year. While most individuals recover from inf...
SBIR
Peptide inhbitors of influenza entry-FAST T...
Between 10% and 20% of the United States population suffer from seasonal influenza each year. While most individuals recover from in...
My Notes
Contact
My Notes